Fund moves
6.8%Stake · was 6.8%
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PODD · NASDAQ · Health Care Equipment
Insulet Corporation (PODD) · oqro.io/stocks/PODD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$133.17−4.06 (−2.96%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Insulet Corporation was filed in the last 90 days. The latest on record was on Jun 4, 2026.
Since 2007, Insulet Corporation insiders reported 52 open-market purchases and 719 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2026.
No open-market sale by an insider of Insulet Corporation (PODD) was filed with the SEC in the last 90 days.
Yes. Members of Congress disclosed 5 trades in Insulet Corporation (PODD) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Gilbert Ray Cisneros Jr. (CA31), Sen. Tina Smith.
Insulet Corporation's next results are expected on Feb 16, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−57.4% (−$179.72) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $312.89 on Nov 20, 2025 to $133.17 on Nov 20, 2026 (−57.4%). Disclosed in this range: 7 insider trades, 0 pre-arranged insider sales, 5 Congress trades, and 45 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Acton, Massachusetts.
Last 12 months
−57.4%
Market value
$9.24B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.33M shares sold short (7.7% of shares outstanding), −5.4% vs the previous count, 4.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Insulet Corporation: 1 fund cut or exited a position in the latest available 13F filings and 1 member of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue, fiscal 2025
$2.71B
+30.7% vs the year before
Net income, fiscal 2025
$247M
As reported in the annual filing
Shares outstanding
69.4M
As of Oct 27, 2026
In fiscal 2025 the company spent $59.6M buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Congress
Traded Oct 20 · disclosed 21 days later
Since the trade −6.6% · S&P 500 −10.3% · to Nov 20
Bought 59% below the 52-week high, RSI 58, 23% under its 200-day average, 13 points behind the S&P 500 over 3 months
Congress
Traded Sep 18 · disclosed 24 days later
Since the trade −5.3% · S&P 500 −9.4% · to Nov 20
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Insulet Corporation over the 12 months to Nov 21, 2026: 6 FDA records and 1 securities case.
Insiders of Insulet Corporation reported 52 open-market purchases and 719 sales since 2007; purchases in 9 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $2.43M4×4 trades | $60K1×1 trade |
| 2025 | $300K1×1 trade | $12.4M13×13 trades |
| 2024 | $21K1×1 trade | $10.3M15×15 trades |
| 2023 | $2.01M3×3 trades | $29M16×16 trades |
| 2022 | — | $22.5M10×10 trades |
| 2021 | — | $26.1M19×19 trades |
| 2020 | — | $21.7M17×17 trades |
| 2019 | — | $16.6M22×22 trades |
| 2018 | — | $8.06M28×28 trades |
| 2017 | $631K5×5 trades | $3.8M6×6 trades |
| 2016 | $3.15M8×8 trades | $863K4×4 trades |
| 2015 | $1.42M8×8 trades | $1.27M7×7 trades |
| 2014 | — | $16.3M29×29 trades |
| 2013 | — | $16.3M30×30 trades |
| 2012 | — | $9.01M45×45 trades |
| 2011 | — | $8.57M37×37 trades |
| 2010 | — | $3.45M27×27 trades |
| 2009 | $76K4×4 trades | $501K12×12 trades |
| 2008 | $305K18×18 trades | $1.14M87×87 trades |
| 2007 | — | $29.4M294×294 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 19, 2025, PODD is down 61.6% and the index fund is up 4.1%: 66 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much PODD moves
Beta 0.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Changed auditor
8-K/A on sec.govTop officer leaving
“Board Resignation In connection with her appointment as Executive Vice President and Chief Financial Officer, Ms.”
3 insiders sold ~$2.36M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
BlackRock, Inc.
13G · passive · Amended · 5.34M shares · filed Oct 27, 2026
Vanguard Capital Management
13G · passive · Crossed 5% · 5.28M shares · filed Apr 30, 2026
AQR Capital Management, LLC
13G · passive · Crossed 5% · 4.75M shares · filed Nov 13, 2026
Sessa Capital IM, L.P.
13G · passive · Crossed 5% · 4.69M shares · filed Nov 16, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Company reports, price and press
Who holds it
Things to keep in mind
Records
FMR LLC cut its stake to 5.6% from 9% · Schedule 13G, 2026
11 certified in FY2026 Q3, vs 11 a year earlier. 11 positions in total, median offered wage $150K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 18, 2026. Read the filing
+27% on the year before ($1.51B)
+44% on the year before ($523M)
−12% on the year before ($38.9M)
The company also reports Total Omnipod products ($2.67B), which group lines above and are not added again.
+26% on the year before ($1.55B)
+44% on the year before ($523M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
Our mission is to transform the lives of people with diabetes. We are primarily engaged in the development, manufacture, and sale of our proprietary Omnipod product platform, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod platform primarily includes our most recent generation Omnipod 5 and its predecessor Omnipod DASH, which eliminate the need for multiple daily injections using syringes or insulin pens or the use of pump and tubing. Omnipod 5, which builds on our Omnipod DASH mobile platform, is a tubeless automated insulin delivery system that integrates with a CGM to manage blood sugar and is fully controlled by a compatible personal smartphone or Omnipod 5 Controller.
Source: SEC EDGAR, Form 10-K filed Feb 18, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Revenue
$842M
+19.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$260M
This quarter $66.4M, a year earlier $100M
Net debt
$378M
Debt $962M, cash $584M, at Sep 30, 2026
Net income, last 12 months
$429M
Operating profit covers interest 9.91x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Revenue and earnings history, 17 fiscal yearsEarnings dates and the stock's moves
And 18 more headings in the filing.
Latest annual report filed Feb 18, 2026, compared with the one filed Feb 21, 2025. Read the filing
The information required by this Item is provided under “Legal Proceedings” in Note 16 to the consolidated financial statements included in Item 8 of this Form 10-K and is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 18, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
A securities lawsuit naming the company as a defendant was filed on Jul 2, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
In re Insulet Corporation Securities Litigation, 1:26-cv-13062Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
Short sale volume: 53.9% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 48.4%. FINRA daily files, to Nov 20, 2026.
Fails to deliver: 15K shares (about $2.01M) were not delivered on time for settlement on Oct 15, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 49.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.2% on ATS, 24.2% with other brokers), above its 26-week average of 46.2%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: SIGMA X2 (13.2%), INTELLIGENT CROSS LLC (12.9%), UBS ATS (12.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
2 approvals or clearances and 4 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 16, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
87%
20 of 23 insider purchases since 2015 came within 30 days after a results announcement
From Insulet Corporation's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Insulet Corporation's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.